---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-22-000133"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T06:18:01.703173+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand Q3 revenue $66.1M (+2% YoY); raises 2022 guidance; completes OmniAb spin-off

## Summary
- Q3 GAAP net income $0.4M ($0.02 EPS) vs $13.7M ($0.80) YoY; adjusted EPS $1.31 vs $1.58.
- Q3 royalty revenue up 27% to $19.8M on Kyprolis, Rylaze, Teriparatide; total revenue $66.1M.
- 2022 guidance raised: total revenue $184-189M (prior $133-146M); adjusted EPS $4.30-$4.45.
- Completed tax-free spin-off of OmniAb on Nov 1; OmniAb began trading as OABI on Nov 2.
- Repurchased $38.6M principal of 2023 Notes for $37.7M; cash & investments $121.4M.

## SEC filing metadata
- accession: 0000886163-22-000133
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/0000886163-22-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/lgnd-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-22-000133
- JSON: https://secwatch.observer/filing/0000886163-22-000133.json
- Plain text: https://secwatch.observer/filing/0000886163-22-000133.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC updated its the three and nine months ended September 30, 2022 guidance (raised).
  - Period: the three and nine months ended September 30, 2022
  - Guidance: raised
  - Result: reported results
  source text: On November 7, 2022, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/0000886163-22-000133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.